IN2012DN00604A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00604A
IN2012DN00604A IN604DEN2012A IN2012DN00604A IN 2012DN00604 A IN2012DN00604 A IN 2012DN00604A IN 604DEN2012 A IN604DEN2012 A IN 604DEN2012A IN 2012DN00604 A IN2012DN00604 A IN 2012DN00604A
Authority
IN
India
Prior art keywords
alkyl
sird2rc
benzyl
phenyl
bond
Prior art date
Application number
Other languages
English (en)
Inventor
R Pendri Yadagiri
H Chen Chung-Pin
S Patel Sunil
M Evans Jeffrey
Liang Jing
R Kronenthal David
L Powers Gerald
Josyula Prasad Siva
T Bien Jeffrey
Shi Zhongping
N Patel Ramesh
Banerjee Amit
Y Chan Yeung
K Rijhwani Sushil
K Singh Ambarish
Wang Shaopeng
Stojanovic Milan
J Kucera David
Polniaszek Richard
Lewis Charles
Thottathil John
Krishnamurty Dhileepkumar
X Zhou Maotang
Vemishetti Purushotham
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IN2012DN00604A publication Critical patent/IN2012DN00604A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/0825—Preparations of compounds not comprising Si-Si or Si-cyano linkages
    • C07F7/083—Syntheses without formation of a Si-C bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/0825—Preparations of compounds not comprising Si-Si or Si-cyano linkages
    • C07F7/0827—Syntheses with formation of a Si-C bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
IN604DEN2012 2002-12-11 2003-12-10 IN2012DN00604A (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43254902P 2002-12-11 2002-12-11
PCT/US2003/039554 WO2004052310A2 (en) 2002-12-11 2003-12-10 Process and intermediates for synthesis entecavir

Publications (1)

Publication Number Publication Date
IN2012DN00604A true IN2012DN00604A (hu) 2015-08-21

Family

ID=32507962

Family Applications (3)

Application Number Title Priority Date Filing Date
IN604DEN2012 IN2012DN00604A (hu) 2002-12-11 2003-12-10
IN605DEN2012 IN2012DN00605A (hu) 2002-12-11 2003-12-10
IN606DEN2012 IN2012DN00606A (hu) 2002-12-11 2003-12-10

Family Applications After (2)

Application Number Title Priority Date Filing Date
IN605DEN2012 IN2012DN00605A (hu) 2002-12-11 2003-12-10
IN606DEN2012 IN2012DN00606A (hu) 2002-12-11 2003-12-10

Country Status (18)

Country Link
US (3) US7034152B2 (hu)
EP (2) EP1644384B1 (hu)
JP (2) JP4726491B2 (hu)
KR (2) KR100944063B1 (hu)
CN (6) CN100379746C (hu)
AU (1) AU2003300884B2 (hu)
BR (2) BR122019020833B8 (hu)
CA (2) CA2508811C (hu)
DK (1) DK1644384T3 (hu)
ES (1) ES2397104T3 (hu)
IL (1) IL168691A (hu)
IN (3) IN2012DN00604A (hu)
MX (1) MXPA05005971A (hu)
PL (2) PL212790B1 (hu)
PT (1) PT1644384E (hu)
SI (1) SI1644384T1 (hu)
TW (1) TWI327568B (hu)
WO (1) WO2004052310A2 (hu)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003279690A1 (en) * 2002-06-27 2004-01-19 F. Hoffmann-La Roche Ag Synthesis of purine derivatives
CN100379746C (zh) * 2002-12-11 2008-04-09 布里斯托尔-迈尔斯斯奎布公司 制备抗病毒药[1S－(1α,3α,4β)]－2－氨基－1,9－二氢－9－[4－羟基－3－(羟甲基)－2－亚甲环戊基]－6H－嘌呤－6－酮的方法
TW200540175A (en) * 2004-06-04 2005-12-16 Bristol Myers Squibb Co Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
US7511139B2 (en) 2004-06-04 2009-03-31 Bristol-Myers Squibb Company Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
CN100379736C (zh) * 2005-05-13 2008-04-09 上海仲夏化学有限公司 恩替卡韦的制备方法
CN1699366A (zh) * 2005-06-03 2005-11-23 北京市典范科技有限责任公司 嘌呤衍生物
US20070060599A1 (en) * 2005-09-09 2007-03-15 Dimarco John D Crystalline forms of [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one
CN101863842B (zh) * 2006-08-24 2012-02-01 江苏正大天晴药业股份有限公司 恩替卡韦中间体及合成方法
CN101130542B (zh) * 2006-08-24 2010-08-04 江苏正大天晴药业股份有限公司 抗病毒核苷类似物的合成方法
CN101838270B (zh) * 2006-08-24 2012-04-18 江苏正大天晴药业股份有限公司 恩替卡韦的中间体及制备
CN101838207B (zh) * 2006-08-24 2012-04-25 江苏正大天晴药业股份有限公司 恩替卡韦的中间体及合成方法
BRPI0622102A2 (pt) * 2006-10-30 2011-12-27 Pirelli pneu para rodas de veÍculo, e, processo para produzir uma composiÇço elastomÉrica reticulÁvel
CN101245068A (zh) * 2007-02-14 2008-08-20 浙江医药股份有限公司新昌制药厂 结晶型态的恩替卡韦及其制备方法和其药物组合物及用途
CN101371841A (zh) * 2007-08-23 2009-02-25 浙江医药股份有限公司新昌制药厂 结晶型恩替卡韦制剂及其制备方法和应用
CN101284799B (zh) 2007-03-23 2013-04-03 浙江医药股份有限公司新昌制药厂 咖啡酰奎宁酸含氮衍生物及其制备方法和其药物组合物及用途
CN101074217B (zh) * 2007-04-04 2010-11-24 北京精华耀邦医药科技有限公司 通过制备色谱分离得到高纯度恩替卡韦关键中间体的方法
CN101397333A (zh) 2007-09-27 2009-04-01 浙江医药股份有限公司新昌制药厂 去羟基万古霉素及其制备方法、和其药物组合物及其用途
CN101723945B (zh) * 2008-10-17 2011-11-02 上海清松制药有限公司 一种制备抗病毒药物恩替卡韦中间体的方法
KR101150254B1 (ko) 2008-12-26 2012-06-12 한미사이언스 주식회사 신규 중간체 및 이를 활용한 엔테카비르 제조방법
CN101828693B (zh) 2009-03-09 2013-01-02 浙江医药股份有限公司新昌制药厂 制备低粘度高流动性类胡萝卜素油悬浮液的方法及其应用
CN101531660B (zh) * 2009-04-14 2012-07-04 安徽贝克联合制药有限公司 一种恩替卡韦一水合物的工业化生产工艺
US8569491B2 (en) * 2009-10-12 2013-10-29 Hanmi Science Co., Ltd Method for preparing entecavir and intermediate used therein
CN101693713B (zh) * 2009-10-28 2011-11-09 福建广生堂药业有限公司 一种恩替卡韦的晶型及其制备方法和药物应用
CN101781301B (zh) * 2010-01-15 2013-04-10 复旦大学 一种制备恩替卡韦的方法
US8481728B2 (en) 2010-02-16 2013-07-09 Scinopharm Taiwan, Ltd. Process for preparing entecavir and its intermediates
CN101805339B (zh) * 2010-04-12 2012-01-11 王明 一种制备恩替卡韦化合物的方法
CA2705953C (en) * 2010-05-31 2018-05-01 Alphora Research Inc. Carbanucleoside synthesis and intermediate compounds useful therein
CN101891741B (zh) * 2010-07-06 2013-01-23 苏州汉德森医药科技有限公司 抗病毒药恩替卡韦的新合成工艺
CN102336754B (zh) 2010-07-15 2017-04-12 浙江奥翔药业股份有限公司 恩替卡韦的合成方法及其中间体化合物
TWI588146B (zh) * 2010-08-30 2017-06-21 浙江奧翔藥業股份有限公司 恩替卡韋的合成方法及其中間體化合物
EP2474548A1 (en) 2010-12-23 2012-07-11 Esteve Química, S.A. Preparation process of an antiviral drug and intermediates thereof
KR101269491B1 (ko) * 2010-12-23 2013-05-31 주식회사 한서켐 엔테카비어 제조방법
CN102225938A (zh) * 2011-04-25 2011-10-26 海南卫康制药(潜山)有限公司 恩替卡韦一水合物新合成工艺
CN102267875B (zh) * 2011-06-17 2013-04-24 常州寅盛药业有限公司 一种恩替卡韦中间体的制备方法
CN102952156A (zh) * 2011-08-29 2013-03-06 南京工业大学 一种抗乙肝药物恩替卡韦中间体及其合成
CN102952135B (zh) * 2011-08-31 2015-04-08 南京工业大学 一种乙肝药物恩替卡韦的合成方法
EP2597096A1 (en) 2011-11-24 2013-05-29 Esteve Química, S.A. Process for preparing entecavir and intermediates thereof
CN103304375B (zh) * 2012-03-12 2017-04-12 浙江奥翔药业股份有限公司 恩替卡韦的合成中间体及其制备方法
CN104822691B (zh) 2012-10-02 2018-04-10 加州理工学院 由活性硅烷对芳族的c‑o键、c‑n键和c‑s键的无过渡金属还原裂解
CN107253967B (zh) 2012-10-02 2021-03-30 加州理工学院 芳族化合物的无过渡金属的甲硅烷基化
CN104017014A (zh) * 2013-02-28 2014-09-03 浙江星月药物科技股份有限公司 一类恩替卡韦的中间体的制备方法，以及中间体
CN104017012A (zh) * 2013-02-28 2014-09-03 浙江星月药物科技股份有限公司 一类恩替卡韦的中间体的制备方法，以及中间体
CN104017015B (zh) * 2013-02-28 2017-04-05 浙江星月药物科技股份有限公司 一类恩替卡韦的中间体的制备方法，以及中间体
CN104017016B (zh) * 2013-02-28 2017-04-05 浙江星月药物科技股份有限公司 一类恩替卡韦的中间体的制备方法，以及中间体
CN104016984A (zh) * 2013-02-28 2014-09-03 浙江星月药物科技股份有限公司 一种恩替卡韦及其中间体的制备方法，以及中间体
CN104177396A (zh) * 2013-05-23 2014-12-03 浙江星月药物科技股份有限公司 恩替卡韦中间体及其制备方法
CN104177397B (zh) * 2013-05-23 2017-10-13 浙江星月药物科技股份有限公司 恩替卡韦中间体及其制备方法
CN104177394B (zh) * 2013-05-23 2017-12-05 浙江星月药物科技股份有限公司 恩替卡韦中间体及其制备方法
GB201313238D0 (en) 2013-07-24 2013-09-04 Avexxin As Process for the preparation of a polyunsaturated ketone compound
EP3177630B1 (en) 2014-08-06 2019-10-23 California Institute of Technology Silylation of aromatic heterocycles by earth abundant transition-metal-free catalysts
KR101640504B1 (ko) 2015-04-15 2016-07-18 동방에프티엘(주) 엔테카비르 일수화물의 제조방법
KR101640503B1 (ko) 2015-04-15 2016-07-18 동방에프티엘(주) 엔테카비르 일수화물의 개선된 제조방법
CN105037363B (zh) * 2015-07-13 2016-08-24 山东罗欣药业集团股份有限公司 一种恩替卡韦化合物的新合成方法
KR102351734B1 (ko) * 2016-04-07 2022-01-14 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 2'-플루오로-6'-메틸렌-탄소환식 아데노신(fmca) 및 2'-플루오로-6'-메틸렌-탄소환식 구아노신(fmcg)의 합성
CN107325122B (zh) * 2017-01-06 2020-05-01 常州博海威医药科技股份有限公司 制备贝前列腺素的新中间体及其制备方法
CN107163049B (zh) * 2017-05-31 2019-06-18 湖北远大生命科学与技术有限责任公司 一种恩替卡韦的制备方法
WO2019080686A1 (zh) * 2017-10-26 2019-05-02 广州市朗启医药科技有限责任公司 恩替卡韦中间体及其合成方法以及恩替卡韦的合成方法
CN109705063B (zh) 2017-10-26 2021-01-01 广州市朗启医药科技有限责任公司 恩替卡韦中间体及其合成方法以及恩替卡韦的合成方法
CN109232637B (zh) * 2018-10-29 2020-11-24 常州博海威医药科技股份有限公司 一种恩替卡韦中间体的制备方法
CN109593090A (zh) * 2019-01-25 2019-04-09 连云港贵科药业有限公司 一种恩替卡韦的合成方法
CN112625041A (zh) * 2020-12-25 2021-04-09 常州博海威医药科技股份有限公司 恩替卡韦的新制备方法以及中间体

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4471130A (en) 1980-08-06 1984-09-11 The Board Of Trustees Of The Leland Stanford Junior University Method for asymmetric epoxidation
US4594439A (en) 1980-08-06 1986-06-10 The Board Of Trustees Of The Leland Stanford Jr. University Method for asymmetric epoxidation
US4900847A (en) 1985-04-04 1990-02-13 Massachusetts Institute Of Technology Catalytic asymmetric epoxidation
JPH01207257A (ja) * 1988-02-15 1989-08-21 Nippon Oil & Fats Co Ltd α−リノレン酸の分離法
US5206244A (en) * 1990-10-18 1993-04-27 E. R. Squibb & Sons, Inc. Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
EP0630897A3 (en) * 1993-06-25 1995-03-01 Bristol Myers Squibb Co 3-hydroxy-4-hydroxymethyl-2-methylene-cyclopentyl purines and pyrimidines.
US5665890A (en) * 1995-03-14 1997-09-09 President And Fellows Of Harvard College Stereoselective ring opening reactions
AU4090697A (en) * 1996-09-03 1998-03-26 Bristol-Myers Squibb Company Improved process for preparing the antiviral agent {1s-(1alpha, 3alpha, 4beta)}-2-amino-1,9-dihydro-9-{4-hydroxy-3-(hydroxymethyl)-2 -methylenecyclopentyl}-6h-purin-6-one
US6127159A (en) * 1997-06-06 2000-10-03 The Board Of Trustees Of The Leland Stanford Junior University Mitofusin genes and their uses
DE60115870T3 (de) 2000-02-29 2010-07-29 Bristol-Myers Squibb Co. Niedrig dosierte entecavir-formulierung und deren verwendung
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
JP2003532643A (ja) * 2000-04-13 2003-11-05 フアーマセツト・リミテツド 肝炎ウイルス感染症を治療するための３’−または２’−ヒドロキシメチル置換ヌクレオシド誘導体
CN100379746C (zh) * 2002-12-11 2008-04-09 布里斯托尔-迈尔斯斯奎布公司 制备抗病毒药[1S－(1α,3α,4β)]－2－氨基－1,9－二氢－9－[4－羟基－3－(羟甲基)－2－亚甲环戊基]－6H－嘌呤－6－酮的方法
US7511139B2 (en) * 2004-06-04 2009-03-31 Bristol-Myers Squibb Company Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
US20070060599A1 (en) * 2005-09-09 2007-03-15 Dimarco John D Crystalline forms of [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one

Also Published As

Publication number Publication date
CN101130552B (zh) 2010-07-28
BRPI0317255B1 (pt) 2019-12-24
EP2433941A1 (en) 2012-03-28
US7550619B2 (en) 2009-06-23
BRPI0317255B8 (pt) 2021-05-25
US20060106215A1 (en) 2006-05-18
WO2004052310A2 (en) 2004-06-24
TW200504065A (en) 2005-02-01
ES2397104T3 (es) 2013-03-04
KR101096830B1 (ko) 2011-12-22
CN101130552A (zh) 2008-02-27
CN101899063A (zh) 2010-12-01
BR122019020833B8 (pt) 2021-07-27
BR0317255A (pt) 2005-11-08
AU2003300884B2 (en) 2010-01-21
CN101130543A (zh) 2008-02-27
IL168691A (en) 2011-09-27
CN102675355B (zh) 2015-05-06
CN101899063B (zh) 2012-12-12
MXPA05005971A (es) 2005-12-05
SI1644384T1 (sl) 2013-02-28
PT1644384E (pt) 2013-01-23
CA2508811A1 (en) 2004-06-24
US7541460B2 (en) 2009-06-02
DK1644384T3 (da) 2013-02-11
PL377263A1 (pl) 2006-01-23
CA2508811C (en) 2014-11-18
TWI327568B (en) 2010-07-21
CN104788485B (zh) 2017-10-03
EP1644384A4 (en) 2009-09-02
KR20050087831A (ko) 2005-08-31
BR122019020833B1 (pt) 2020-09-01
EP1644384B1 (en) 2012-10-31
US20060106216A1 (en) 2006-05-18
EP1644384A2 (en) 2006-04-12
JP4726491B2 (ja) 2011-07-20
CN1747959A (zh) 2006-03-15
KR20090084979A (ko) 2009-08-05
CN102675355A (zh) 2012-09-19
CN101130543B (zh) 2011-06-08
CN104788485A (zh) 2015-07-22
AU2003300884A1 (en) 2004-06-30
JP2006509800A (ja) 2006-03-23
IN2012DN00606A (hu) 2015-06-12
CN100379746C (zh) 2008-04-09
JP2010222365A (ja) 2010-10-07
PL397715A1 (pl) 2012-03-26
PL212790B1 (pl) 2012-11-30
WO2004052310A3 (en) 2005-03-03
CA2735485A1 (en) 2004-06-24
KR100944063B1 (ko) 2010-02-24
IN2012DN00605A (hu) 2015-06-12
US7034152B2 (en) 2006-04-25
US20040192912A1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
IN2012DN00604A (hu)
AU2003282983A8 (en) Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods
CY1113362T1 (el) Διαρυλ-αιθερες, ως ανταγωνιστης οπιοειδους υποδοχεως
DE60335359D1 (de) Phthalazinonderivate
ATE361345T1 (de) Metalloxyphthalocyaninverbindungen
RS50470B (sr) Inhibitori ćelijske adhezije
CY1108738T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για την αγωγη του πονου
TW200616969A (en) Imidazole compound
CY1113578T1 (el) 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια
MY134701A (en) Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
HK1081199A1 (en) Process and intermediates for the preparation of (1r,2s,5s)-6,6-dimethyl-3- azabicyclo [3,1,0] hexane-2-carboxylates or salts thereof
ATE440833T1 (de) Antithrombotische diamide
WO2003016291A1 (fr) Activateur du recepteur $g(d) sensible au proliferateur de peroxysome
ATE292634T1 (de) Inhibitoren der alpha-l beta-2 vermittelten zelladhäsion
DE60214591D1 (en) Pyrazolpyrimidinfungizide
IN2012DN02609A (hu)
AU2003254852A8 (en) Fused heterocyclic compounds as peptidase inhibitors
IN2012DN00758A (hu)
EA200500201A1 (ru) Новый способ синтеза (7-метокси-1-нафтил)ацетонитрила и его применение при синтезе агомелатина
MXPA05002307A (es) Composiciones antimicrobianas.
BRPI0510335A (pt) composto heterocìclico
MX2008001956A (es) Dihidroxiantraquinonas y su uso.
MXPA05013751A (es) Procedimiento e intermediarios para la preparacion de 3-(amino)-3-ciclobutilmetil-2-hidroxi-propionamida o sus sales.
EP1656127A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER
WO2004030664A3 (en) New compounds for the inhibition of undesired cell proliferation and use thereof